)
At Week 52 of Treatment (SINUS-52), DUPIXENT Demonstrated1:
IN NC SCORE
LSM difference between DUPIXENT 300 mg Q2W + INCS (n=35) and placebo + INCS (n=44): -1.13 (95% CI: -1.49, -0.77) (-1.34 from a baseline score of 2.38 vs -0.21 from a baseline score of 2.49, respectively).1
IN NPS
LSM difference between DUPIXENT 300 mg Q2W + INCS (n=35) and placebo + INCS (n=44): -2.57 (95% CI: -3.27, -1.87) (-2.54 from a baseline score of 5.87 vs 0.03 from a baseline score of 6.06, respectively).1
IN LMK-CT SCORE
LSM difference between DUPIXENT 300 mg Q2W + INCS (n=35) and placebo + INCS (n=44): -6.86 (95% CI: -8.62, -5.10) (-7.27 from a baseline score of 19.71 vs -0.41 from a baseline score of 19.07, respectively).1
Analysis was not multiplicity controlled; results are descriptive; definitive conclusions cannot be made.1
27% of patients enrolled in SINUS-52 presented with NSAID‑ERD2
Nasal congestion/obstruction (NC) score (range 0-3): reduced score indicates improvement.2
Nasal polyp score (NPS), the sum of right and left nostril scores (range 0-4 for each nostril, range 0-8 in total) as evaluated by nasal
endoscopy: reduced score indicates improvement.2
Lund-Mackay computed tomography (LMK-CT) score (range 0-24): reduced score indicates improvement.2
INCS, intranasal corticosteroid; LSM, least squares mean; NSAID-ERD, nonsteroidal anti-inflammatory drug–exacerbated respiratory
disease; Q2W, once every 2 weeks.
Use of DUPIXENT for the CRSwNP indication in patients aged 12-17 years is supported by evidence from studies of DUPIXENT as add-on maintenance
treatment in adults with inadequately controlled CRSwNP.2
Explore the Safety Data
and Study Designs
Dosage and
Administration
See the recommended dosing and
administration options for patients
on DUPIXENT.